KLK3 and cancer: Base on further work using NPCR data [83], revised guidelines now recommend that all men with very low-risk disease (i.e., low risk plus additional features: PSA density < 0.15 ng/mL/cc, ≤4 positive cores and <8 mm total cancer in cores) be managed by AS [84].